Print

Lay Description

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

Category

  • Child Health
  • Nervous System
  • Brain & Nervous System
IRB Number
20180742HU
NCT Number
NCT03126916
Open to Enrollment
Yes

Eligibility

Eligible Ages
Between 365 Days and 30 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Regulatory Point of Contact
Jaclyn Hung
+1 (210) 450-5358
hungj@uthscsa.edu

Regulatory Point of Contact
Anne-Marie Langevin
(210) 567-7460
langevin@uthscsa.edu

Principal Investigator
Anne-Marie Langevin